Lexaria Bioscience Extensive Program Designed to Support Commercial Discussions.
January 16, 2024, Lexaria Bioscience (LEXX) announced a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with the global pharmaceutical companies.
Lexaria Bioscience patented drug delivery technology DehydraTECHTM . . .
This content is for paid subscribers.
Today’s Highlights
January 16, 2024
